Smart Animal, Inc. is a focused enterprise supporting the development of its flagship device for a single indication (labeling self antibodies with an imaging tag).  We will support this device with secure patents, pre-clinical studies and Regulatory-approved documentation.  The device will be manufactured by contractors or through licensing agreements.  

This device is intended to be used in the field of Personalized Medicine, but is also effective for platform applications.  The device is a cost-effective, single-use, disposable unit.  It meets the definition of a diagnostic tool and of a therapeutic.  The device is non-invasive, does not require any external power source, and is compact and lightweight.  It can be utilized in an out-patient or clinic setting and treatment can be administered by trained technicians or nursing staff.  The unit can also be applied in the field (for military use) or in Third-World settings.

Profits will be generated through sale of the device and by securing licenses with biotech and pharmaceutical companies interested in directing their drug candidate to its individual site of interest.

Several key factors will stimulate interest in licensing use of the device, including:

• The ability to image the sites of distribution in the patient prior to the therapeutic application of the active drug. 
• Reduction of the therapeutic dosage, due to the targeting action of the device.  This will reduce both cost and toxicity of the therapeutic treatment relative to systemic drug administration.
• The innate properties of antibody conjugation reduce the need for aggressive modification of unstable therapeutics, to provide increased stability and prolonged circulation kinetics.
• The relatively low risk to the patient of a non-invasive technique which incorporates proven technology.
• Regulatory-approved manufacture and operation to minimize the time to clinic.  
• Action across a broad spectrum of clinical applications follows from the proven success of a single application (imaging sites of immunological activity).

Smart Animal was conceptualized and founded by Gary McNeil and Catherine McNeil.  Their goal was to apply their life experiences to develop a cross-effective therapy applicable to different patient populations which individually may not provide a profitable return to conventional biotech investments.  It is also their desire to provide hope and cures to patients who are inoperable or who fail to respond to conventional therapies.

Smart Animal's founder and Chief Scientific Officer is Gary L. McNeil.  He has been an active member of the biotech community for over 15 years, and has worked in the field of immunology, recombinant protein purification and characterization, device design, GMP medical device manufacturing and downstream process development.  He obtained a Master's Degree in Protein Biochemistry (University of Guelph, 1992), a Bachelor's degree majoring in Chemistry (St. Francis Xavier University, 1989) and a Diploma of Engineering (St. Francis Xavier University, 1987).  He currently holds one device oriented patent and is published in the journals Biochemistry and Cell Biology and Biological Chemistry.

Smart Animal's President is Catherine E. McNeil, who is also head of the Clinical Department.  She attended St. Francis Xavier University's Nursing program from 1986-1989.  She has worked in the medical field as an RNA in a critical care Hospital and in an assisted living center.  She has also worked for several years for a prominent DMD in Cambridge, MA.

Smart Animal's Business / Accounting Department is maintained by Celeste M. Pardy.  She holds a business associate’s degree and has been balancing books and keeping businesses honest for decades.

Smart Animal’s IT/Marketing Department is maintained by Michael A. Maliska.  Yes, I know, I’m sorry, but he is the best we could get.